--- title: "NHS Framework Agreement, Branded Medicines for London and South of England" ocid: "ocds-h6vhtk-02ac57" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02ac57" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02ac57.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02ac57.json" source: "Find A Tender Service" current_stage: "Award" buyer: "NHS ENGLAND" published: "2021-09-17" --- # NHS Framework Agreement, Branded Medicines for London and South of England Buyer: NHS ENGLAND Current stage: Award OCID: ocds-h6vhtk-02ac57 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02ac57) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02ac57.json) ## Summary The NHS Framework Agreement for Branded Medicines, catering to London and the South of England, has reached the award stage and is now complete. The initiative is organised by NHS England, with procurement initiated on 1st September 2021 and scheduled to last until 31st August 2023, with the potential for up to 24 months of extensions at the discretion of the authority. The procurement process followed an open method, and the industry classification falls under pharmaceutical products (CPV code 33600000). The contract was awarded based on price criteria. This tender presents significant opportunities for pharmaceutical companies, particularly those focused on branded medicines, to expand their market presence within the NHS framework. Businesses that are well-suited to compete include small and medium-sized enterprises as well as larger entities with the capability to deliver high-quality pharmaceutical products under the competitive bidding process. Given the extensive reach of NHS England, suppliers can expect substantial orders that can contribute to overall business growth. ## Notice NHS Framework Agreement, Branded Medicines for London and South of England and NHS Framework for the Midlands & East and North of England Regions - Bevacizumab. ### Lot Information CM/PHR/20/5598/01 - NHS Framework LONDON Branded Medicines - Tranche B. CM/PHR/20/5598/01 - NHS Framework for LONDON Branded Medicines - Tranche B.Period of framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 Months Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5598/02 - NHS Framework LONDON Branded Medicines - Annual Tranche. CM/PHR/20/5598/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/05 - NHS Framework SOUTH of England Annual Tranche. CM/PHR/20/5598/05 - NHS Framework for the SOUTH of England Annual Tranche.Period of Framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/03 - NHS Framework SOUTH of England Tranche A. CM/PHR/20/5598/03 - NHS Framework for the SOUTH of England Tranche A.Period of Framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5598/04- NHS Framework SOUTH of England - Tranche B. CM/PHR/20/5598/04- NHS Framework for SOUTH of England - Tranche B.Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months CM/PHR/20/5598/06 - NHS Framework Midlands & East and NofE - Bevacizumab CM/PHR/20/5598/06 - NHS Framework for the Midlands & East and North of England Regions - Bevacizumab Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 6 months ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/023223-2021 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large, SME | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 17 Sep 2021 | | Submission deadline | 4 Jun 2021 | | Future notice date | Not specified | | Award date | 18 Aug 2021 | | Contract period | 31 Aug 2021 - 28 Feb 2022 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £1,110,294,056 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Cancelled | | Awards status | Active | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Additional buyers | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) | | Locality | RUNCORN | | Post town | Warrington | | Postcode | WA7 2ES | | Country | England | | ITL 1 | TLE Yorkshire and The Humber | | ITL 2 | TLE4 West Yorkshire | | ITL 3 | TLE42 Leeds | | Local authority | Leeds | | Electoral ward | Little London & Woodhouse | | Westminster constituency | Leeds Central and Headingley | | Delivery location | TLI London | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 42 | | Supplier names | ACCORD-UK; ALLERGAN; AMGEN; ASTRAZENECA; AVENTIS PHARMA LTD T/A SANOFI; BAYER; BIOGEN; BRISTOL MYERS SQUIBB; CELLTRION HEALTHCARE UNITED KINGDOM; CHUGAI; CST PHARMA; DAIICHI SANKYO; DR.REDDY'S LABORATORIES (UK; ELI LILLY; FERRING PHARMACEUTICALS; GEDEON RICHTER; GILEAD SCIENCES; IPSEN; JANSSEN-CILAG; MERCK SERONO; MERCK SHARPE AND DOHME (UK; MERZ; MORNINGSIDE PHARMAEUTICALS; MYLAN; NAPP PHARMACEUTICALS; NOVO NORDISK; ORGANON PHARMACEUTICALS; PFIZER; PHARMACOSMOS; PROFILE PHARMA; ROCHE PRODUCTS; SANDOZ; SOBI (SWEDISH ORPHAN BIOVITRUM; TAKEDA; TECHDOW PHARMA ENGLAND; TETRIS PHARMA LTS; TEVA; THORNTON AND ROSS; UCB; UL GLOBAL PHARMA; VIFOR PHARMA; ZENTIVA PHARMA | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 17 Sep 2021 at 15:04 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/023223-2021 - 30 Apr 2021 at 14:19 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/009446-2021 ## Notice URLs - http://health.atamis.co.uk - http://health.atamis.co.ukCandidates - https://supplierregistration.cabinetoffice.gov.ukand - https://www.england.nhs.uk/ - https://www.england.nhs.uk// - https://www.gov.uk/courts-tribunals ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02ac57. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02ac57.json.